From Thomas Jefferson U and Fox Chase: Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer

J Thorac Dis. 2014 Apr;6(4):387-398.

Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.

Palmer JD, Zaorsky NG, Witek M, Lu B.

Author information

• 1 Department of Radiation Oncology, Kimmel Cancer Center and Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA ; 2 Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Abstract

The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.